LON:AVO - Advanced Oncotherapy Share Price, Forecast & News

Advanced Oncotherapy trades on the London Stock Exchange (LON) under the ticker symbol "AVO."

1 brokers have issued 12 month price objectives for Advanced Oncotherapy's shares. Their forecasts range from GBX 155 to GBX 155. On average, they expect Advanced Oncotherapy's stock price to reach GBX 155 in the next twelve months. This suggests a possible upside of 297.4% from the stock's current price. View Analyst Price Targets for Advanced Oncotherapy.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advanced Oncotherapy in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Advanced Oncotherapy.

Media coverage about AVO stock has been trending extremely negative on Saturday, according to InfoTrie. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Advanced Oncotherapy earned a media sentiment score of -4.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Advanced Oncotherapy.

Some companies that are related to Advanced Oncotherapy include Zynex (ZYXI), Creo Medical Group (CREO), Medica Group (MGP), Hamilton Thorne (HTL), Cyclopharm (CYC), Impedimed (IPD), Electromed (ELMD), Electromed (ELMD), REVA Medical (RVA), Kromek Group (KMK), MRI Interventions (MRIC), Protech Home Medical (PHM), Oventus Medical (OVN), Resonance Health (RHT) and LBT Innovations (LBT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Advanced Oncotherapy investors own include UK Oil & Gas (UKOG), Avesoro Resources (ASO), BMR Group (BMR), Lancashire (LRE), Sirius Minerals (SXX), Oxford BioMedica (OXB), Renishaw (RSW), GW Pharmaceuticals PLC- (GWPH), Scancell (SCLP) and Bahamas Petroleum (BPC).

Shares of AVO and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

One share of AVO stock can currently be purchased for approximately GBX 39.

Advanced Oncotherapy has a market capitalization of £95.10 million. Advanced Oncotherapy employs 93 workers across the globe.View Additional Information About Advanced Oncotherapy.

The official website for Advanced Oncotherapy is http://www.advancedoncotherapy.com/.

Advanced Oncotherapy's mailing address is Third Fl Clearwater HSE, 4-7 Manchester Street, LONDON, W1U 3AE, United Kingdom. The company can be reached via phone at +44-20-36178728.